Lonza adding new fill-finish line at its biologics manufacturing site in China
Swiss CDMO’s expansion at recently opened Guangzhou plant expected to be ready by next year
Lonza, a contract development and manufacturing organization (CDMO) serving the pharma, biotech and nutrition sectors, will be investing toward launching drug product manufacturing capabilities at its site in Guangzhou, China.
Specifically, the funds will go toward installing an aseptic drug product fill-and-finish production line at the near 183,000 square-foot current good manufacturing practice (cGMP) mammalian facility that began operating during Q2 of this year. Anticipated completion is 2022.
The future fill-finish production line—featuring the filling of liquid and lyophilized items—will primarily support global and domestic customers with supply for clinical trials and commercial batches in China. The introduction of drug product manufacturing at the Guangzhou (CN) site will provide a combined drug substance and drug product manufacturing service offering for customers, according to Lonza, which is headquartered in Switzerland.
"The investment in drug product manufacturing capabilities at Lonza Guangzhou not only demonstrates our commitment to the Chinese market but also marks an important milestone in achieving our long-term ambition of increasing drug product capacity and addressing growing customer demand for an end-to-end drug product solution,” says Hong Pan, general manager, China, Lonza. "Through the expansion of our services at Lonza Guangzhou, we will have the capability to support our customers with the late-stage clinical trial and commercial development of potentially life-saving treatments."
